Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe).

Lansigan F, Costa CA, Zaki BI, Yen SP, Winer ES, Ryan H, Findley D, Metzler SR, Shaw L, Toaso B, MacKenzie TA, Chen Y, Beaven AW.

Clin Cancer Res. 2019 Jun 26. doi: 10.1158/1078-0432.CCR-18-3755. [Epub ahead of print]

PMID:
31243122
2.

Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.

Rizzieri DA, Sand GJ, McGaughey D, Moore JO, DeCastro C, Chao NJ, Vredenburgh JJ, Gasparetto C, Long GD, Anderson E, Foster T, Toaso B, Adams D, Niedzwiecki D, Gockerman JP.

Cancer. 2004 Jun 1;100(11):2408-14.

3.

Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.

Rizzieri DA, Akabani G, Zalutsky MR, Coleman RE, Metzler SD, Bowsher JE, Toaso B, Anderson E, Lagoo A, Clayton S, Pegram CN, Moore JO, Gockerman JP, DeCastro C, Gasparetto C, Chao NJ, Bigner DD.

Blood. 2004 Aug 1;104(3):642-8. Epub 2004 Apr 20.

PMID:
15100153

Supplemental Content

Support Center